Stevens Johnson syndrome-toxic epidermal necrolysis Overlap induced by sulfasalazine treatment: a case report
##plugins.themes.academic_pro.article.main##
Abstract
SUMMARY:
Introduction: Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening and severe adverse cutaneous drug reactions characterized by epidermal detachment presenting as blisters and areas of denuded skin. SJS, SJS-TEN overlap and TEN differ only by their extent of skin detachment.
Case presentation: We report here the case of a young woman (33- year old) admitted to the dermatological unit for epidermal detachment (at 18% of the body surface area), blisters, red macular and papular lesions, developed 15 days after administration of sulfasalazine. Prior to this, she complained of fever and discomfort upon swallowing. Skin biopsy had shown epidermal necrosis compatible with Stevens Johnson Syndrome and Toxic Epidermal Necrolysis. As the epidermal detachment was between 10% and 30%, she was diagnosed as a Stevens Johnson Syndrome/Toxic Epidermal Necrolysis overlap. The course was favorable 17 days after stopping the drug and starting a symptomatic treatment.
Conclusion: Practitioners and patients need to be aware of the initial clinical signs of severe cutaneous adverse drug reactions such as fever, influenza-like symptoms, dysphagia or burning eyes. Early discontinuation of medication remains the best way to improve prognosis of patients with Stevens Johnson’s Syndrome and Toxic Epidermal Necrolysis.
Introduction: Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening and severe adverse cutaneous drug reactions characterized by epidermal detachment presenting as blisters and areas of denuded skin. SJS, SJS-TEN overlap and TEN differ only by their extent of skin detachment.
Case presentation: We report here the case of a young woman (33- year old) admitted to the dermatological unit for epidermal detachment (at 18% of the body surface area), blisters, red macular and papular lesions, developed 15 days after administration of sulfasalazine. Prior to this, she complained of fever and discomfort upon swallowing. Skin biopsy had shown epidermal necrosis compatible with Stevens Johnson Syndrome and Toxic Epidermal Necrolysis. As the epidermal detachment was between 10% and 30%, she was diagnosed as a Stevens Johnson Syndrome/Toxic Epidermal Necrolysis overlap. The course was favorable 17 days after stopping the drug and starting a symptomatic treatment.
Conclusion: Practitioners and patients need to be aware of the initial clinical signs of severe cutaneous adverse drug reactions such as fever, influenza-like symptoms, dysphagia or burning eyes. Early discontinuation of medication remains the best way to improve prognosis of patients with Stevens Johnson’s Syndrome and Toxic Epidermal Necrolysis.
Keywords:
Severe cutaneous adverse reactions ; Stevens-Johnson Syndrome ; Toxic epidermal necrolysis ; SJS-TEN overlap ; Sulfasalazine##plugins.themes.academic_pro.article.details##
References
- Grull R, Nelle M, Schaible T: Toxic epidermal necrolysis and Stevens- Johnson Syndrome: A review. Crit Care Med 2011, 39:1521- 1532.
- Strom J: Toxic epidermal necrolysis (Lyell's syndrome). A report on four cases with three deaths. Scan J Infect Dis 1969, 1:209-216.
- Maddocks JL, Slater DN: Toxic epidermal necrolysis, agranulocytosis and erythroid hypoplasi associated with sulphasalazine. J R Soc Med 1980, 73:587-8.
- Pearel RK, Nelson RL, Prasard ML et al: Serious complications of sulfasalazine. Dis Colon Rectum 1985, 29:201-2.
- Jullien D, Wolkenstein P, Roupie E et al: Toxic epidermal necrolysis after sulfasalazine treatment of mild psoriatic arthritis: warning on the use of sulfasalazine for a new indication. Arthritis Rheum 1995, 38:573.
- Martin L, Hazouard E, Michalak-Provost S et al: Épithéliolyse respiratoire toxique fatale. Desquamation suraiguë trachéo-bronchique lors d'un syndrome de Stevens-Johnson. Rev Pneumol Clin 2001, 57:297-301.
- Borras-Blasco J, Navarro-Ruiz A, Matarredona J et al: Photo-induced Stevens- Johnson syndrome due to sulfasalazine therapy. Ann Pharmacother 2003, 37:1241-3.
- Tremblay L, Pineton de Chambrun G, De Vroey B et al: Stevens- Johnson syndrome with sulfasalazine treatment: Report of two cases. J Crohn colitis 2011, 5:457-460.
- Mockenhaupt M: Severe cutaneous adverse reactions. In Braun-Falco's Dermatology. 3rd edition. Edited by Burgdof WHC, Plewing G, Wolff HH, Landthala M (Eds). Springer Medizin Verlag, Heidelberg-Germany 2008:473-483.
- Harr T, French LE: Toxic epidermal necrolysis and Stevens-Jonhnson syndrome. Orphanet Journal of Rare diseases 2010, 5:39.
- Mockenhaupt M: The current understanding of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Expert Rev Clin Immunol 2011, 7:803-815.
- Roujeau JC, Kelly JP, Naidi L et al: Medication use and the risk of SJS or TEN. N Engl J Med 1995, 333:1600-1607.
- Mockenhaupt M, Vibaud C, Dunant A et al: SJS and TEN: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study. J Invest Dermatol 2008, 128:35-44.
- Hung SI, Chung WH, Liou LB et al: HLA-B 801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A, 2005, 102:4134-9.
- Chung WH, Hung SI, Hong HS et al: A marker for Stevens-Johnson syndrome. Nature 2004, 428:486.